Notes to the Consolidated Financial Statements of the Bayer Group

1. Key Data by Segment and Region

Key Data by Segment

 

 

HealthCare

 

CropScience

 

Covestro

 

Reconciliation

 

 

 

 

 

Pharmaceuticals

 

Consumer Health

 

CropScience

 

Covestro

 

All Other Segments

 

Corporate Center and Consolidation

 

Group

 

 

2014

2015

 

2014

2015

 

2014

2015

 

2014

2015

 

2014

2015

 

2014

2015

 

2014

2015

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2014 figures restated

Net sales (external)

 

12,052

13,745

 

7,023

9,129

 

9,494

10,367

 

11,651

11,982

 

1,112

1,097

 

7

4

 

41,339

46,324

Change

 

+7.7%

+14.0%

 

+4.4%

+30.0%

 

+7.7%

+9.2%

 

+3.7%

+2.8%

 

−4.9%

−1.3%

 

−42.9%

 

+5.6%

+12.1%

Currency-adjusted change

 

+11.6%

+9.9%

 

+8.3%

+25.0%

 

+11.4%

+2.3%

 

+4.5%

−5.1%

 

−4.4%

−0.8%

 

−42.9%

 

+8.5%

+6.2%

Intersegment sales

 

99

38

 

8

5

 

49

34

 

59

64

 

2,243

2,249

 

(2,458)

(2,390)

 

Net sales (total)

 

12,151

13,783

 

7,031

9,134

 

9,543

10,401

 

11,710

12,046

 

3,355

3,346

 

(2,451)

(2,386)

 

41,339

46,324

Other operating income

 

184

137

 

150

129

 

208

644

 

81

67

 

16

69

 

71

64

 

710

1,110

EBIT

 

2,371

2,807

 

1,099

1,243

 

1,806

2,103

 

555

635

 

(11)

(39)

 

(425)

(499)

 

5,395

6,250

EBIT before special items

 

2,657

3,061

 

1,144

1,589

 

1,838

1,881

 

598

967

 

21

43

 

(425)

(472)

 

5,833

7,069

EBITDA before special items

 

3,699

4,195

 

1,658

2,224

 

2,360

2,416

 

1,187

1,659

 

200

238

 

(419)

(466)

 

8,685

10,266

Gross cash flow

 

2,745

2,737

 

1,153

1,384

 

1,835

1,941

 

961

1,113

 

331

147

 

(318)

(323)

 

6,707

6,999

Capital invested

 

17,288

17,661

 

19,718

21,172

 

11,772

11,854

 

11,019

11,293

 

1,197

757

 

(117)

(217)

 

60,877

62,520

CFROI

 

15.3%

14.1%

 

9.8%

5.9%

 

15.3%

14.8%

 

6.0%

7.0%

 

 

 

11.7%

9.6%

Net cash flow

 

3,266

2,863

 

1,065

1,458

 

950

761

 

880

1,452

 

360

26

 

(824)

287

 

5,697

6,847

Equity-method income (loss)

 

1

1

 

 

(1)

 

(14)

(9)

 

 

 

(13)

(9)

Equity-method investments

 

2

3

 

6

11

 

4

 

215

227

 

 

1

 

223

246

Assets

 

19,377

19,477

 

19,387

20,263

 

12,676

14,230

 

9,347

9,360

 

2,253

2,324

 

7,194

8,263

 

70,234

73,917

Capital expenditures

 

668

701

 

202

288

 

699

737

 

647

514

 

261

311

 

7

5

 

2,484

2,556

Additions to noncurrent assets from acquisitions

 

2,645

(122)

 

10,153

126

 

166

98

 

27

 

 

821

 

13,785

129

Depreciation, amortization and impairments

 

1,075

1,180

 

514

684

 

552

535

 

594

733

 

179

195

 

6

6

 

2,920

3,333

of which impairment losses

 

39

48

 

69

73

 

100

35

 

11

69

 

6

4

 

 

225

229

of which impairment loss reversals

 

 

(1)

 

 

(2)

 

 

 

(2)

(1)

Liabilities

 

7,075

7,487

 

3,079

3,172

 

5,214

5,344

 

3,520

3,740

 

4,682

4,814

 

26,446

23,915

 

50,016

48,472

Research and development expenses

 

1,878

2,333

 

386

501

 

974

1,089

 

210

262

 

29

32

 

60

64

 

3,537

4,281

Number of employees (as of Dec. 31)

 

39,069

38,927

 

20,130

18,894

 

23,060

23,496

 

14,122

15,770

 

20,256

19,015

 

734

709

 

117,371

116,811

Key Data by Region

 

 

Europe

 

North America

 

Asia / Pacific

 

Latin America / Africa / Middle East

 

Reconciliation

 

Total

 

 

2014

2015

 

2014

2015

 

2014

2015

 

2014

2015

 

2014

2015

 

2014

2015

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2014 figures restated

Net sales (external) – by market

 

15,312

15,949

 

9,953

12,740

 

9,067

10,264

 

7,007

7,371

 

 

41,339

46,324

Change

 

+5.2%

+4.2%

 

+7.0%

+28.0%

 

+5.7%

+13.2%

 

+4.4%

+5.2%

 

 

+5.6%

+12.1%

Currency-adjusted change

 

+6.3%

+5.2%

 

+8.4%

+10.8%

 

+8.7%

+1.4%

 

+12.9%

+8.1%

 

 

+8.5%

+6.2%

Net sales (external) – by point of origin

 

16,999

17,704

 

9,787

12,450

 

8,820

10,023

 

5,733

6,147

 

 

41,339

46,324

Change

 

+5.6%

+4.1%

 

+6.6%

+27.2%

 

+5.1%

+13.6%

 

+4.5%

+7.2%

 

 

+5.6%

+12.1%

Currency-adjusted change

 

+6.7%

+5.1%

 

+8.0%

+9.4%

 

+8.2%

+1.5%

 

+14.8%

+11.3%

 

 

+8.5%

+6.2%

Interregional sales

 

9,096

10,865

 

3,294

3,995

 

719

828

 

545

695

 

(13,654)

(16,383)

 

Other operating income

 

324

572

 

146

109

 

70

107

 

170

322

 

 

710

1,110

EBIT

 

3,481

4,019

 

808

1,490

 

594

546

 

937

694

 

(425)

(499)

 

5,395

6,250

Assets

 

29,378

33,420

 

23,035

20,522

 

8,540

9,492

 

5,479

5,804

 

3,802

4,679

 

70,234

73,917

Capital expenditures

 

1,286

1,424

 

639

588

 

403

402

 

156

142

 

 

2,484

2,556

Depreciation, amortization and impairments

 

1,795

1,860

 

655

834

 

381

496

 

83

137

 

6

6

 

2,920

3,333

Liabilities

 

32,120

28,914

 

12,298

13,461

 

3,436

3,583

 

1,473

1,688

 

689

826

 

50,016

48,472

Research and development expenses

 

2,412

2,947

 

866

1,051

 

198

214

 

61

69

 

 

3,537

4,281

Number of employees (as of Dec. 31)

 

54,595

55,892

 

15,819

15,985

 

30,132

28,818

 

16,825

16,116

 

 

117,371

116,811